Skip to content

Finished goods at other companies

Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$311.3M+127%
Gross profit$43.5M
Operating income-$92.7M-16.9%
Net income-$94.4M-28.9%
EPS (diluted)-$3.25-24.5%

Balance sheet

See full
Cash & equivalents$232.2M+23.1%
Total debt$377.3M+187%
Total equity$543.5M-23.5%
Total assets$1.2B+23.1%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$3.8M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.66B+64.2%
Enterprise value$11.81B+67.5%
P/S10.3×-12.1×

Profitability

See full
Gross margin96.5%
Operating margin-27.7%-12.2pp
Net margin-27.3%-12.0pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-49.3%-0.8pp
Debt / equity0.7×+0.5×
Current ratio3.5×-2.4×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s finished goods?
Madrigal Pharmaceuticals, Inc. (MDGL) reported finished goods of $5.81M in Q1 2026.
How has Madrigal Pharmaceuticals, Inc.'s finished goods changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s finished goods increased by 36.0% year-over-year, from $4.27M to $5.81M.